openPR Logo
Press release

Reclaim247 Leads the Charge in Helping UK Drivers Recoup Mis-Sold Car Finance

05-01-2025 11:10 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Reclaim247 Leads the Charge in Helping UK Drivers Recoup

Amid a huge FCA probe, Reclaim247 is now representing thousands of UK motorists who may be able to claim compensation for mis-sold car finance agreements. As a leading claims management firm, Reclaim247 leads the national movement to address the long-neglected practice of Discretionary Commission Arrangements (DCAs) in automotive finance.

Fair Play in the Light of Unfair Practices

An investigation by the FCA into historical car finance compensation claims has shined a much needed spotlight on DCAs - car dealership-lender deals that saw sellers hike interest rates for higher commission - often without the buyer's knowledge. These opaque agreements have disproportionately affected UK drivers, many of whom were unaware they had been overcharged.

"We've been fighting for financial fairness long before the FCA launched its formal inquiry," says Andrew Franks, Co-Founder of Reclaim247 [https://www.reclaim247.co.uk/]. "Our mission has always been clear-empower consumers with knowledge and support them through the claims process with integrity and urgency."

The Scale of the Problem

According to FCA estimates, millions of finance agreements may have included DCA clauses. Reclaim247's early response and infrastructure readiness have made the company a leader in handling mis-sold car finance UK claims.

Franks says, "Drivers trusted dealerships to provide clear financing options. Instead, some paid thousands more than necessary. We're here to help them reclaim what's rightfully theirs."

Why This Matters Now

It is a time-sensitive window for affected drivers to file a complaint. So while the FCA reviews the matter, experts foresee increased claims activity as awareness spreads. Reclaim247 has expanded to meet the demand and give clients the attention they deserve.

"This is more than just a compliance issue-it's about justice," explains Franks. "With rising living costs, recovering lost funds could make a huge difference in people's lives."

How Drivers Can Take Action

Reclaim247 makes car finance claims [https://www.reclaim247.co.uk/] simpler for users. The claimant provides the details of their past car finance agreements - some as far back as 2007 - and Reclaim247 assesses eligibility and files on their behalf.

"Many do not even realise they were mis-sold," Franks says. "If you didn't understand your interest rate or the commission structure, you may have a claim."

Building Consumer Trust With Transparency

What sets Reclaim247 apart is not its proactive approach, but its ethical commitment. The company offers free initial assessments, clear terms, and no-win, no-fee arrangements.

"We're not just processing claims-we're restoring confidence in the system," says Franks. "And we're proud to lead that charge."

A Moment of Change

With the FCA's review poised to reshape consumer protections in the finance sector, Reclaim247 is calling on all drivers who purchased vehicles using hire purchase or personal contract purchase (PCP) agreements to check their eligibility.

"This is a rare moment where the industry is being held accountable," concludes Franks. "Don't miss your chance to be part of that change."

About Reclaim247

Reclaim247 is a UK-based consumer claims specialist dedicated to financial justice. With years of experience in challenging unfair financial practices, the company combines legal expertise with customer-first service to help consumers recover funds lost through mis-selling and misconduct.

Media Contact
Company Name: Reclaim247
Contact Person: Andrew Franks
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=reclaim247-leads-the-charge-in-helping-uk-drivers-recoup-missold-car-finance]
City: Manchester, M20 2DW
Country: United Kingdom
Website: https://www.reclaim247.co.uk/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Reclaim247 Leads the Charge in Helping UK Drivers Recoup Mis-Sold Car Finance here

News-ID: 3996254 • Views:

More Releases from ABNewswire

Myelofibrosis Market Outlook 2034 - Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight
Myelofibrosis Market Outlook 2034 - Clinical Trials, Market Size, Medication, Pr …
Myelofibrosis Market Include Incyte Corporation, Keros Therapeutics, Karyopharm Therapeutics, Celgene Corporation, PharmaEssentia, Novartis, SecuraBio, Pharmaxis, Novartis Oncology, AstraZeneca, Cellenkos, Jacobio Pharmaceuticals, Ohmoncology, Geron Corporation, AbbVie, Sierra Oncology, Galecto Biotech, Actuate Therapeutics, Kartos Therapeutics, Menarini Group, Telios Pharma, Novartis Pharmaceuticals, NS Pharma, Celgene/Bristol-Myers Squibb, MorphoSys, Imago BioSciences, Roche, and others. Myelofibrosis Market Summary The Myelofibrosis market in the 7MM is set to grow significantly, rising from USD 2.6 billion in 2025 to USD
Kid Connecticut Showcases Full Catalog of Authentic Innovation
Kid Connecticut Showcases Full Catalog of Authentic Innovation
Rising independent artist Kid Connecticut is making waves across streaming platforms with a catalog that blends sharp lyricism, genre-bending production, and unfiltered authenticity. With every release, Kid Connecticut has built a reputation as a creator who refuses to follow the industry blueprint. Instead, he offers listeners a body of work that reflects growth, resilience, and originality while capturing the reality of an artist evolving in real time. From his earliest tracks
Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline 2025: Innovations by 180+ Global Leaders - DelveInsight | Featuring GenSight Biologics, Ultragenyx Pharmaceutical, MeiraGTx
Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline 2025: Innovations …
Adeno-Associated Virus (AAV) Vectors in Gene Therapy companies are Nanoscope Therapeutics, REGENXBIO, Astellas Gene Therapy, GeneCradle Therapeutics, Asklepios BioPharmaceutical, 4D Molecular Therapeutics, Adverum Biotechnologies, Rocket Pharmaceuticals, Innostellar Biotherapeutics, Passage Bio, Aspa Therapeutics, Solid Biosciences, Lantu Biopharma, Ascidian Therapeutics, Decibel Therapeutics, Sio Gene Therapies, and others. As the use of Adeno-Associated Virus (AAV) vectors in gene therapy expands globally, there is increasing demand for safer and more effective treatment options, addressing conditions
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market: Epidemiology, Therapies, Companies, DelveInsight | Key players include AstraZeneca, Boehringer Ingelheim, Genentech/Roc
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market: …
The total market size of EGFR mNSCLC in the 7MM was ~USD 4,000 million in 2023. Emerging EGFR-NSCLC therapies-such as TAGRISSO, GILOTRIF/GIOTRIF, TARCEVA, RYBREVANT, VIZIMPRO, IRESSA, PORTRAZZA, Aumolertinib, Zipalertinib, Furmonertinib, BDTX-1535, Dato-DXd, JIN-A02, NX-019, STX-721, and ORIC-11-are expected to drive market growth in the coming years. DelveInsight's report, "Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) - Market Insights, Epidemiology, and Market Forecast-2034," provides a comprehensive analysis of EGFR-NSCLC, including historical

All 5 Releases


More Releases for Reclaim247

Reclaim247 Surpasses 400000 Clients Amid Growing Consumer Concern Over Car Finan …
Manchester, UK - Reclaim247 today announced that more than 400,000 UK drivers have now registered their interest in receiving support regarding potential issues with historical car finance agreements. This important milestone reflects growing public interest about the transparency of motor finance arrangements. The company is helping motorists who think they are affected by past finance agreements - especially ones made between 2007 and 2021. An initial eligibility review from Reclaim247 helps
Reclaim247 Boosts Car Finance Claims Support as Drivers Revisit PCP Agreements
With concerns growing over hidden interest charges, Reclaim247 is stepping up efforts to help drivers understand past PCP and car finance agreements, and what action might now be possible. Reclaim247 is increasing its support for drivers across the UK who are re-examining older car finance agreements, particularly Personal Contract Purchase (PCP) and Hire Purchase contracts. The company, co-founded by Andrew Franks, has seen a sharp rise in the number of people wanting
More Than 400,000 Drivers Trust Reclaim247 to Reclaim Car Finance Compensation
Reclaim247, the UK's leading car finance claims firm, has officially surpassed 400,000 claims filed in its short history, staking a powerful claim in what was decidedly a transformative 2024 for consumers in the turbulent car finance world. The milestone reflects a surge in consumer action during what many in the industry are calling a "watershed moment" for financial accountability in the auto sector. The company, known for its no win, no
Reclaim247 Supports UK Drivers in Recovering Compensation for Mis-Sold Car Finan …
A flood of complaints about mis-sold car finance has shaken the UK financial sector, as thousands of drivers uncover hidden commissions that quietly inflated their repayments. According to new data from the Financial Ombudsman Service (FOS), over 18,600 complaints were filed in just four months between September and December 2024, making car finance the most complained-about financial product in Britain - overtaking credit cards for the first time. The sharp rise in